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Abstract 
Synergy between micro-nanotechnology and regenerative medicine can lead to new tools for health 
improvement. In this study, we investigate the efficacy of electrospun scaffolds - fabricated using 
clinically approved collagen – as supports for cardiomyoblast culture. The scaffolds were prepared 
using non-toxic solvents and crosslinking agents and characterized by scanning electron microscopy 
and contact angle measurements. Among different types of collagen samples, we found that 
atelocollagen can produce better quality of electrospun fibers than acid and basic fibrous collagen. 
Our results also show that the cell culture performance can be improved by adjusting the crosslinking 
conditions. Typically, increasing the concentration of citric acid of the cross-link agents from 5% to 
10% w/w and the post-crosslink baking time from 1.5 to 2.5 h led to significant increases of the 
cellular colonization of the scaffold, showing three-dimensional growth of cardiac cells due to the 
specific morphology of the fibrous scaffolds. Finally, in vivo tests of the biocompatibility of the 
fabricated scaffolds have been done using a mouse model of dilated cardiomyopathy. As expected, 
the biocompatibility of the scaffold was found excellent and no visible inflammation was observed 
after the implantation up to two weeks. However, 5% citric acid electrospun collagen scaffolds was 
less resistant in vivo, proving again the importance of the processing parameter optimization of the 
electrospun scaffolds.  
 
Highlights: 
 Fabrication of collagen scaffold by electrospinning. 
 Non-toxic collagen solvents and crosslinking agents. 
 Biocompatible grafted collagen scaffolds in mice. 
 Control of cardiomyoblast growth in collagen by crosslinking treatment. 
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Engineered scaffolds have been widely used as structural and functional supports on which cells are 
seeded for the generation of cell therapy products. In the field of cardiac therapy, this approach is 
challenging but holds a real promise for improving function of the chronically failing myocardium [1]. 
Previously, a large number of investigations have been devoted to the culture of cardiac cells using 
scaffolds made of synthetic polymers. In particular, nanofibrous scaffolds obtained by electrospinning 
of poly-L-lactic acid (PLLA) and poly-(caprolactone) (PCL) could be produced for the formation of 
functional cardiac cell layers [2]. However, because of the lack of cell affinity these synthetic polymers 
are inherent less attractive than natural polymers - such as collagen, fibrinogen, elastin - for in vivo 
applications [3]. Among them, collagen constitutes one of the main proteins of the extracellular matrix, 
and this allows for a close simulation of the natural fibrillar structure of cardiac tissue [4]. Accordingly, 
it is interesting to consider electrospun collagen scaffolds as supports and carriers of cardiac cells that 
can be implanted for repair of the failing myocardium [5]. 
Different types of clinically approved collagen are now available but the ability of making fibrous 
scaffolds out of them has yet to be demonstrated. One of the issues is the crosslinking process, which 
uses chemical reagents to render the fibrous structures stable in the culture medium and after 
implantation. The most common crosslinkers for collagen fibers are glutaraldeyde - well known for its 
efficiency but somehow toxic - and combinations of 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide 
hydrochloride (EDC) and N-hydroxysuccinimide (NHS) – a system which is less toxic but often causes 
a film-like morphology after the immersion of the fibers in water [6] [7]. Alternatively, a citric acid (CA) 
based system has been recently applied and shown the requested biocompatibility [8]. 
In this work, we study the electrospinning parameters of clinically approved collagen in order to 
produce optimal nanofiber scaffolds for three-dimensional culture of cardiac cells. In particular, we 
were interested in creating a patch form of scaffold that can be used for therapy purposes. Our results 
show that the colonization of cardiac cells is critically dependent on the crosslink parameters and that 
our collagen scaffolds are fully compatible with the implantation requirements, thereby providing a 
way towards a scaffold based cardiac cell therapy. 
 
2. Materials and Methods 
2.1 Collagen solutions preparation and electrospinning 
Different types of clinically approved collagen, including atelocollagen, acid fibrous, basic fibrous  
were provided by Biom’Up (Saint-Priest, France) in form of dry material after lyophilization. For 
electrospinning, the raw collagen materials were dissolved using a solvent system containing ethanol, 
water and a variety of salts [7]. Specifically, the buffer solution  is composed of the following salts 
dissolved in deionized water: potassium chloride, sodium chloride, potassium phosphate monobasic, 
sodium phosphate dibasic heptahydrate. The salts concentration is 20x in the collagen buffer solution. 
The final solvent system consists of buffer solution and ethanol in a ratio 1:1 v/v with a collagen 
concentration of 16 % w/v. 
For the crosslinking of the collagen scaffolds a system containing CA, glycerol as extending agent 
and sodium hypophosphite (SHP) as catalyst was used [8]. The three crosslinking components were 
added to the collagen solution before the electrospinning. Different concentrations of CA and SHP 
were studied: 5% CA with 2.1% SHP and 10% CA with 4.2% SHP, keeping constant the glycerol 
amount to 3% (weight percentage based on the weight of collagen).  
In electrospinning, the solution is fed through a thin needle opposite to a collecting plate and a high 
voltage is applied to form a jet of the solution that travels from the needle to the grounded collecting 
plate (fig. 1). In our study, the collagen solution was loaded to a syringe with a 23 gauge blunt needle 
and the flow rate was controlled via a pump at 1ml/h. By applying voltage of 13.5 kV and keeping a 
distance of 5cm between the needle tip and the grounded collector, fibers were deposited to the latter 
at room temperature (20±2
 o
C). After 8 minutes of continuous electrospinning, collagen scaffolds were 




Figure 1. Schematic representation 
of the electrospinning apparatus. 
 
 
Figure 2. Images of the atelocollagen 
fibrous scaffold a) deposited onto 




2.2 Post-electrospinning treatment 
After electrospinning, a crosslinking post-treatment was applied in order to make the scaffolds 
insoluble in cell culture medium and facilitate their handling. The carboxyl groups of CA reacted with 
the additional hydroxyl groups introduced by glycerol in order to form covalent bridges between the 
collagen fibers. The scaffolds were baked at 150
 o
C for three different periods (1.5h, 2h, 2.5h). 
The crosslinked scaffolds were mounted onto handing devices for biologic assays. Cell crowns® 
holders were utilised for this purpose and then placed in 24-well plates for cell culture.  
 
2.3 Characterization methods 
The structure of the electrospun collagen scaffolds was studied after the steps of electrospinning and 
crosslinking treatment using scanning electron microscopy (SEM) and contact angle measurements. 
The SEM measurements were performed using the e-LiNE (Raith). A thin gold layer of 5nm was 
deposited prior to measurements and images at different magnifications were obtained on at least 
three different areas in the same sample. The measurements were performed under extra high 
tension of 10kV. 
The contact angle measuring instrument was the Drop Shape Analyzer - DSA 30 (Krüss). The sessile 
drop method was utilized and the measurements took place at room temperature (20 
o
C). The volume 
of the applied droplets of deionized water was 1.5 μl. The contact angle data were obtained by 
averaging over five measurements in different areas on the sample surface. 
 
2.4 Cardiomyoblasts culture 
The H9c2 cell line derived from embryonic rat heart tissue was used in this study. Cells were cultured 
in high glucose DMEM+Glutamax supplemented with 10% foetal bovine serum and 1% 
penicillin/streptomycin. They were seeded on the collagen scaffold after passage using trypsin-EDTA. 
After two days of culture, scaffolds were washed with PBS and fixed with 1% paraformaldehyde 
solution. After 2 washing steps, they were incubated with 5% bovine serum albumin (BSA) during 1 
hour. Then Alexa Fluor® 488 Phalloidin (Life technologies) was used to stain the cells. After 3 washes 
in PBS, collagen scaffolds were mounted with mowiol. Images were captured using a motorized 
confocal laser scanning microscope (LSM 700, Zeiss). 
 
2.5 Epicardial grafts 
All procedures were approved by our institutional Ethics Committee and complied with the European 
legislation (Directive 2010/63/EU) on animal care. Conditionally-invalidated serum response factor 
(SRF) mice (MHC-MerCreMer:Sf/Sf) were used as recipients [9]. The Cre-mediated excision of floxed 
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SRF alleles in the heart was induced by daily intraperitoneal tamoxifen (28 g/g/day; Sigma-Aldrich, 
France) injections on 3 consecutive days with the day of the first injection counted as day 1. Three 
weeks after tamoxifen administration, the animals underwent a left lateral thoracotomy after 
intraperitoneal ketamine (100 mg/kg; Merial, France)-xylazin (10 mg/kg; Bayer, Germany) 
anaesthesia and tracheal ventilation. Analgesia was performed for 2 days after surgery with a 10 
mg/kg subcutaneous injection of ketoprofen (Merial). Acellular collagen scaffolds were sutured on the 
left ventricle. All animals were sacrificed at the end of experiment by cervical dislocation. Hearts were 
immediately removed, fixed in Tissue-Tek (Sakura, USA) and frozen in liquid nitrogen-cooled 
isopentane until they were sliced into 8 to 12-µm thick cryosections using a cryostat. The sections 
were stained with HE (hematoxylin and eosin) as described by Dubowitz [10]. Images were taken with 
an inverted microscope (Leica DMIL) equipped with a digital camera (Qicam, Qimaging). 
 
 
3. Results and Discussion 
3.1 Characterization of crosslinked scaffolds 
3.1.1 SEM 
Amongst the different collagen types, atelocollagen derived from native collagen by enzymatic 
extraction exhibited the best performance both in terms of dissolution to the benign solvent system 
(within few hours at room temperature) and of electrospinning ability. The acid fibrous collagen 
required one week to be dissolved and the basic fibrous collagen was not compatible with the used 
solvent system resulting to a partial dissolution after 3 weeks. All the types of collagen were tested for 
their ability to create fiber mats by electrospinning. Acid and basic fibrous types ended up to 
nanofibers with knots and it was not able to create a thick enough mat that could be unpeeled from 
the collector. These types of nanofibers might be used for the surface modification of cell culture 
substrates e.g. by directly depositing the electrospun fibers on the latter, but cannot be used as 
implantable scaffolds which is our intention. On the other hand, atelocollagen proved to be able to 
create uniform continuous fibers without knots (Fig. 3) that can be easily unpeeled from the collector 
(Fig. 2). Fig. 3a and 3b show the atelocollagen mesh-structured scaffold and demonstrate, at a higher 
magnification, the uniformity of the fibers with a diameter of 1±0.3μm. 
 
 
Figure 3. SEM images of atelocollagen fibers after electrospinning at different magnifications: (a) 1x 
and (b) 10x. 
 
After the post-electrospinning crosslinking treatment, the samples were characterized before and after 
their immersion into deionized water in order to verify the efficacy of the method. Neither the duration 
of baking nor the concentration of the cross-linkers did affect the fibers morphology before the 
immersion to water. 
Conversely, the morphology of the samples after the immersion in water varied in relation with the 
concentrations of CA and SHP. At low concentrations, loss of porosity was observed as shown in 
fig.4a, whereas the morphology was significantly improved for 10% CA and 4.2% SHP (fig. 4b,c). 
 




Figure 4. SEM images of crosslinked collagen scaffolds after immersion in water (a) 5% CA, (b) 10% 
CA and (c) 10% CA at higher magnification. 
 
3.1.2 Contact angle measurements 
Collagen scaffolds before and after the crosslinking treatment were then characterized. Figure 5a 
shows the surface of a non-crosslinked scaffold, five seconds after the deposition of water droplet, 
which spread immediately all over the scaffold, causing scaffold dissolution. For the measurements of 
the crosslinked scaffolds with 10% CA, the latter were immersed in water and then placed in cell 
crowns® holders. The water contact angles obtained with dry samples showed that the surfaces did 
not dissolve, but are hydrophilic with a contact angle of 50
°
 just five seconds after the droplet 
deposition (fig. 5b). The water contact angles decreased down to 30
°
 just 60 seconds after the droplet 
deposition, which further indicates the porosity of the samples (fig. 5c). 
 
Figure 5. Images of water droplets on collagen scaffolds with 10% CA (a) uncrossliked, (b,c) 
crosslinked captured at different time after droplet deposition. 
 
3.2 Biological validation of the scaffolds 
3.2.1 In Vitro Studies: Cellularisation of collagen scaffolds 
The electrospun collagen scaffolds were successfully used for culture of H9c2 cells. Figure 6 shows a 
confocal microscopic image after immunostaining for actin and nuclei which demonstrates the 
colonization of the 10 % CA scaffold. Clearly, the cells were spread all over the scaffold and show a 
nice structure of their actin filaments (the blue cells are more deeply sunk into the collagen than the 
others). The cells seem to spread more extensively as the baking time was longer. It should be noted 
that, by increasing the baking time, the stiffness should be enhanced, which could be more desirable 
in our case. Moreover, comparing the different concentrations of CA, it is obvious that the higher 




Figure 6. Confocal images of H9c2 cardiomyoblasts on the electrospun collagen scaffold (10% CA) 
after 48h cell culture. 
 
Preliminary experiments with human pluripotent stem cell-derived cardiac progenitors have also been 
performed, showing a promising efficacy of the fabricated collagen scaffold. The next step will be the 
implantation of the cell-seeded scaffold in mice with failing myocardium with the hope that the scaffold 
may provide an optimal microenvironment to the cells, thereby allowing them to improve heart 
function, either by integrating structurally within the recipient tissue or, more likely, by activating 
endogenous reparative pathways. 
 
3.2.2 In Vivo Studies: implantation of acellular collagen scaffolds 
In this study, we used a double transgenic mouse model which allows the inactivation of SRF only in 
cardiomyocytes as tamoxifen-inducible Cre recombinase expression is under the control of the 
cardiomyocyte-specific alpha myosin heavy chain promoter [9]. Five days after tamoxifen injection 
there is a drop of SRF mRNA and protein levels. Then, mice exhibit a progressive dilated 
cardiomyopathy, leading to a non-ischaemic heart failure and death within 10 weeks. This model 
allows a timed control of the functional deterioration, thereby allowing a better comparison between 
treated and non-treated mutant animals. 
Non-ischaemic heart failure can only be treated by drugs in contrast to ischaemic cardiomyopathies. If 
the treatment fails, the only remaining options are heart transplantation or permanent implantation of 
assist devices [11]. Our goal is to develop cell therapy as a new tool for the cure of non-ischaemic 
cardiomyopathies. The first issue to address is the biocompatibility of the nano-fabricated collagen 
scaffold. To this end, 10 conditionally-invalidated serum response factor (SRF) mice (aMHC-
MerCreMer:Sf/Sf) were transplanted with the 10% CA collagen scaffold. The biocompatibility was 
found excellent, as the scaffold was detectable from 2 days (4 mice) to 2 weeks (6 mice) after the 
implantation, with no visible inflammation (fig. 7, A & B). It was slightly degraded over time as its 
thickness only decreased to 60% after two weeks of implantation (fig. 7, C). This decreased thickness 
also indicates that the inflammation is very low. Moreover, the porosity of the electrospun collagen 
scaffold did not significantly change between 2 and 14 days, indicating that the structure of the patch 
is not altered (fig. 7, D). It should be noted, that we also implanted 5 % CA electrospun collagen 
scaffolds in 12 mice. The results were very similar to the 10 % CA after 2 days of implantation. But 
after 2 weeks, we were not able to find the scaffolds in 62.5% of the implanted mice. This suggests 
that the 5% CA electrospun collagen scaffolds seem to be less resistant in vivo. Together, all these 
results demonstrate the good biocompatibility of the electrospun clinically-approved collagen scaffold 




Figure 7. Biocompatibility of the electrospun collagen scaffold. Hearts of aMHC-MerCreMer:Sf/Sf mice 
were explanted 2 days (A) or 14 days (B) after implantation. The mean thickness (C) and the porosity 
(D) of the grafted patches were analyzed. 
 
4. Conclusions 
The present work has been designed to create a cardiac patch which can be used as a cell carrier for 
therapy purposes. Among different approaches, electrospinning appears to be the simplest but yet 
versatile method for the fabrication of fibrous scaffolds from a large variety of materials. Then, the 
challenge is to find the most suited material and processing parameters. Although the electrospinning 
techniques have been well documented, few of them applied to cardiac cell therapy which requires a 
full control of the porous size, the mechanical stiffness and the bio-reactivity or bio-degradability of the 
scaffold. As a first step of our approach, we produced nanofibers by electrospinning of a clinically 
proven collagen dissolved in a non-toxic solvent system in contrary to the widely used  1,1,1,3,3,3 
hexafluoro-2-propanol [3]. In addition, we chose a citric acid-based system for cross-linking of the 
electrospun nanofibers, which makes our fabrication process compatible to the therapy purposes. 
After crosslinking, the collagen fibrous scaffold could be easily mounted on a standard device for in 
vitro studies. This should allow more systematic investigations to elucidate the dependence of cell 
migration and three-dimensional colonization as a function of pore size and thickness of the scaffold. 
The fabricated nanofiber scaffolds could also be used for in-vivo testing. Our preliminary results have 
shown the feasibility of implantation of this patch. Finally, the mechanical stiffness of the scaffold will 





This work was supported by the French National Research Agency (ANR-12-RPIB-0015) and by the 
Fondation de l’Avenir (ET2-658). P.J. was supported by a fellowship from the Fondation Lefoulon-
Delalande and S.B. from the Conseil Régional d’Ile de France (DIM Biothérapies). M.K. would like to 
thank Ms. Anne-Laure Vayssade from Microfluidique, MEMs and Nanostructures Laboratory of ESPCI 
for allowing her using their contact angle measurement instrument. 
 
References 
[1] P. Menasché, V. Vanneaux, J.-R. Fabreguettes, A. Bel, L. Tosca, S. Garcia, V. Bellamy, Y. 
Farouz, J. Pouly, O. Damour, M.-C. Périer, M. Desnos, A. Hagège, O. Agbulut, P. Bruneval, G. 
Tachdjian, J.-H. Trouvin, and J. Larghero, “Towards a clinical use of human embryonic stem 
cell-derived cardiac progenitors: a translational experience.,” Eur. Heart J., May 2014. 
[2] D. Castellano, M. Blanes, B. Marco, I. Cerrada, A. Ruiz-Saurí, B. Pelacho, M. Araña, J. A. 
Montero, V. Cambra, F. Prosper, and P. Sepúlveda, “A comparison of electrospun polymers 
reveals poly(3-hydroxybutyrate) fiber as a superior scaffold for cardiac repair.,” Stem Cells 
Dev., vol. 23, no. 13, pp. 1479–90, Jul. 2014. 
[3] S. a Sell, M. J. McClure, K. Garg, P. S. Wolfe, and G. L. Bowlin, “Electrospinning of 
collagen/biopolymers for regenerative medicine and cardiovascular tissue engineering.,” Adv. 
Drug Deliv. Rev., vol. 61, no. 12, pp. 1007–19, Oct. 2009. 
[4] S. Corda, J. L. Samuel, and L. Rappaport, “Extracellular matrix and growth factors during heart 
growth.,” Heart Fail. Rev., vol. 5, no. 2, pp. 119–30, Jun. 2000. 
[5] J. A. Matthews, G. E. Wnek, D. G. Simpson, and G. L. Bowlin, “Electrospinning of Collagen 
Nanofibers,” Biomacromolecules, vol. 3, no. 2, pp. 232–238, Mar. 2002. 
[6] G. P. Huang, S. Shanmugasundaram, P. Masih, D. Pandya, S. Amara, G. Collins, and T. L. 
Arinzeh, “An investigation of common crosslinking agents on the stability of electrospun 
collagen scaffolds.,” J. Biomed. Mater. Res. A, pp. 1–10, May 2014. 
[7] B. Dong, O. Arnoult, M. E. Smith, and G. E. Wnek, “Electrospinning of collagen nanofiber 
scaffolds from benign solvents.,” Macromol. Rapid Commun., vol. 30, no. 7, pp. 539–42, Apr. 
2009. 
[8] Q. Jiang, N. Reddy, S. Zhang, N. Roscioli, and Y. Yang, “Water-stable electrospun collagen 
fibers from a non-toxic solvent and crosslinking system.,” J. Biomed. Mater. Res. A, vol. 101, 
no. 5, pp. 1237–47, May 2013. 
[9] A. Parlakian, C. Charvet, B. Escoubet, M. Mericskay, J. D. Molkentin, G. Gary-Bobo, L. J. De 
Windt, M.-A. Ludosky, D. Paulin, D. Daegelen, D. Tuil, and Z. Li, “Temporally controlled onset 
of dilated cardiomyopathy through disruption of the SRF gene in adult heart.,” Circulation, vol. 
112, no. 19, pp. 2930–9, Nov. 2005. 
[10] S. C. A. Dubowitz V, Muscle Biopsy: A Practical Approach. Saunders Ltd., 2006. 
[11] A. J. Clegg, D. A. Scott, E. Loveman, J. L. Colquitt, P. Royle, and J. Bryant, “Clinical and cost-
effectiveness of left ventricular assist devices as a bridge to heart transplantation for people 
with end-stage heart failure: a systematic review and economic evaluation.,” Eur. Heart J., vol. 
27, no. 24, pp. 2929–38, Dec. 2006.  
 
